DGX vs. CRL
Compare and contrast key facts about Quest Diagnostics Incorporated (DGX) and Charles River Laboratories International, Inc. (CRL).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: DGX or CRL.
Correlation
The correlation between DGX and CRL is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
DGX vs. CRL - Performance Comparison
Loading data...
Key characteristics
DGX:
1.26
CRL:
-0.70
DGX:
2.22
CRL:
-0.87
DGX:
1.27
CRL:
0.87
DGX:
1.85
CRL:
-0.50
DGX:
8.32
CRL:
-1.43
DGX:
3.67%
CRL:
27.54%
DGX:
21.94%
CRL:
53.84%
DGX:
-49.46%
CRL:
-78.23%
DGX:
-0.30%
CRL:
-69.24%
Fundamentals
DGX:
$19.87B
CRL:
$6.92B
DGX:
$7.90
CRL:
-$0.62
DGX:
1.56
CRL:
0.12
DGX:
1.96
CRL:
1.72
DGX:
2.84
CRL:
2.14
DGX:
$10.16B
CRL:
$4.02B
DGX:
$3.31B
CRL:
$1.28B
DGX:
$1.95B
CRL:
$546.00M
Returns By Period
In the year-to-date period, DGX achieves a 19.13% return, which is significantly higher than CRL's -23.63% return. Over the past 10 years, DGX has outperformed CRL with an annualized return of 11.40%, while CRL has yielded a comparatively lower 6.90% annualized return.
DGX
19.13%
8.65%
12.01%
25.80%
12.65%
11.40%
CRL
-23.63%
32.93%
-24.91%
-36.39%
-3.89%
6.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
DGX vs. CRL — Risk-Adjusted Performance Rank
DGX
CRL
DGX vs. CRL - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Quest Diagnostics Incorporated (DGX) and Charles River Laboratories International, Inc. (CRL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
DGX vs. CRL - Dividend Comparison
DGX's dividend yield for the trailing twelve months is around 1.71%, while CRL has not paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DGX Quest Diagnostics Incorporated | 1.71% | 1.96% | 2.02% | 2.08% | 1.40% | 1.85% | 1.99% | 2.34% | 1.83% | 1.72% | 2.07% | 1.92% |
CRL Charles River Laboratories International, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
DGX vs. CRL - Drawdown Comparison
The maximum DGX drawdown since its inception was -49.46%, smaller than the maximum CRL drawdown of -78.23%. Use the drawdown chart below to compare losses from any high point for DGX and CRL. For additional features, visit the drawdowns tool.
Loading data...
Volatility
DGX vs. CRL - Volatility Comparison
The current volatility for Quest Diagnostics Incorporated (DGX) is 7.86%, while Charles River Laboratories International, Inc. (CRL) has a volatility of 19.98%. This indicates that DGX experiences smaller price fluctuations and is considered to be less risky than CRL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
DGX vs. CRL - Financials Comparison
This section allows you to compare key financial metrics between Quest Diagnostics Incorporated and Charles River Laboratories International, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DGX vs. CRL - Profitability Comparison
DGX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported a gross profit of 863.00M and revenue of 2.65B. Therefore, the gross margin over that period was 32.5%.
CRL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Charles River Laboratories International, Inc. reported a gross profit of 317.73M and revenue of 984.17M. Therefore, the gross margin over that period was 32.3%.
DGX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported an operating income of 346.00M and revenue of 2.65B, resulting in an operating margin of 13.1%.
CRL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Charles River Laboratories International, Inc. reported an operating income of 74.67M and revenue of 984.17M, resulting in an operating margin of 7.6%.
DGX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported a net income of 220.00M and revenue of 2.65B, resulting in a net margin of 8.3%.
CRL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Charles River Laboratories International, Inc. reported a net income of 25.47M and revenue of 984.17M, resulting in a net margin of 2.6%.